Published in Osteoporos Int on March 12, 2003
Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis. Osteoporos Int (2006) 1.79
An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos Int (2006) 0.96
Cancer treatment-related bone loss: a review and synthesis of the literature. Curr Oncol (2008) 0.93
The effect of composition on ion release from Ca-Sr-Na-Zn-Si glass bone grafts. J Mater Sci Mater Med (2009) 0.83
The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporos Int (2009) 0.79
On some osteoporosis analyses. Osteoporos Int (2005) 0.75
Strontium Ranelate: Long-Term Efficacy against Vertebral, Nonvertebral and Hip Fractures in Patients with Postmenopausal Osteoporosis. Ther Adv Musculoskelet Dis (2010) 0.75
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med (1995) 10.99
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int (2000) 4.85
Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med (1990) 3.76
Treatment of postmenopausal osteoporosis. N Engl J Med (1998) 2.83
Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med (1999) 2.01
Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med (1998) 1.81
An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res (1993) 1.60
Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab (2002) 1.57
Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration. J Bone Miner Res (1996) 1.48
Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up) J Clin Endocrinol Metab (1997) 1.48
The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone (1996) 1.38
Prevention of postmenopausal bone loss by tiludronate. Lancet (1990) 1.05
In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Eur J Pharmacol (2002) 1.01
Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effect in mice. Metabolism (2002) 0.99
A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int (2001) 0.98
Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos Int (2002) 0.92
The use of different dual X-ray absorptiometry brands in a multicenter clinical trial: consequences and limits. J Clin Densitom (1999) 0.84
Prevention of early postmenopausal bone loss with cyclical etidronate. J Endocrinol Invest (2000) 0.75
Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res (1987) 24.27
Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med (1992) 9.86
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int (1997) 5.82
Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int (2005) 5.54
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab (2005) 3.67
Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet (1996) 3.18
Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet (1984) 2.85
Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study. Lancet (1996) 2.83
Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int (2002) 2.82
Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int (1999) 2.70
Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res (1996) 2.61
Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ (1994) 2.61
Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab (2000) 2.34
Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest (1997) 2.33
Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J (1980) 2.29
Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone (2000) 2.24
Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab (1997) 2.04
Measurement of bone mineral content of the lumbar spine by dual energy x-ray absorptiometry in normal children: correlations with growth parameters. J Clin Endocrinol Metab (1990) 1.83
Mean wall thickness of trabecular bone packets in the human iliac crest: changes with age. Calcif Tissue Res (1978) 1.83
Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study. Bone (1996) 1.80
Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest (1993) 1.78
Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet (1994) 1.71
How hip and whole-body bone mineral density predict hip fracture in elderly women: the EPIDOS Prospective Study. Osteoporos Int (1998) 1.70
Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res (2001) 1.62
Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab (2000) 1.58
Glucocorticoid-induced inhibition of osteoblastic bone formation in ewes: a biochemical and histomorphometric study. Osteoporos Int (1993) 1.58
The degree of mineralization is a determinant of bone strength: a study on human calcanei. Bone (2004) 1.54
Healthy elderly French women living at home have secondary hyperparathyroidism and high bone turnover in winter. EPIDOS Study Group. J Clin Endocrinol Metab (1996) 1.53
Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet (1988) 1.50
Prevention and treatment of osteoporosis. Aging (Milano) (1995) 1.50
Fluoride and vertebral fractures. Lancet (1990) 1.48
Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration. J Bone Miner Res (1996) 1.48
Calcium and vitamin D supplements: effects on calcium metabolism in elderly people. Am J Clin Nutr (1987) 1.46
Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res (1997) 1.42
Which screening strategy using BMD measurements would be most cost effective for hip fracture prevention in elderly women? A decision analysis based on a Markov model. Osteoporos Int (2006) 1.41
Dual energy X-ray absorptiometry in patients with lower limb reflex sympathetic dystrophy syndrome. J Rheumatol (1996) 1.38
Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone. Lancet (1979) 1.30
Changes in bone remodeling rate influence the degree of mineralization of bone. Connect Tissue Res (2002) 1.30
Treatment of osteoporosis with fluoride, calcium, and vitamin D. Orthop Clin North Am (1981) 1.29
The degree of mineralization of bone tissue measured by computerized quantitative contact microradiography. Calcif Tissue Int (2002) 1.28
Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment. Bone (2004) 1.25
Addressing the musculoskeletal components of fracture risk with calcium and vitamin D: a review of the evidence. Calcif Tissue Int (2006) 1.24
The management of Paget's disease of bone. N Engl J Med (1997) 1.23
Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer (1983) 1.23
Structural determinants of hip fracture in elderly women: re-analysis of the data from the EPIDOS study. Osteoporos Int (2005) 1.22
Different morphometric and densitometric parameters predict cervical and trochanteric hip fracture: the EPIDOS Study. J Bone Miner Res (1997) 1.22
Mean wall thickness and formation periods of trabecular bone packets in idiopathic osteoporosis. Calcif Tissue Int (1981) 1.21
Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif Tissue Int (1983) 1.21
Influence of mature adipocytes on osteoblast proliferation in human primary cocultures. Bone (2000) 1.20
Skeletal fluorosis: histomorphometric analysis of bone changes and bone fluoride content in 29 patients. Bone (1989) 1.16
Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds. Endocrinology (1983) 1.16
Ultrasound discriminates patients with hip fracture equally well as dual energy X-ray absorptiometry and independently of bone mineral density. J Bone Miner Res (1995) 1.16
Quality of life and vertebral osteoporosis. Osteoporos Int (1992) 1.15
Fibrous dysplasia of bone. Baillieres Best Pract Res Clin Rheumatol (2000) 1.15
Quantitative histology of myeloma-induced bone changes. Br J Haematol (1982) 1.15
Effects of disodium dichloromethylene diphosphonate on bone loss in paraplegic patients. J Clin Invest (1981) 1.14
[Aluminum poisoning in renal dialysis patients: bone histology. Value of quantitative bone biopsy]. Presse Med (1984) 1.10
Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women. J Bone Miner Res (1994) 1.09
Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int (2004) 1.08
Effects of bisphosphonates on matrix mineralization. J Musculoskelet Neuronal Interact (2002) 1.08
Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases. J Clin Invest (1980) 1.07
Influence of remodeling on the mineralization of bone tissue. Osteoporos Int (2009) 1.07
Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiometry. J Clin Densitom (1999) 1.07
In osteoporotic women treated with strontium ranelate, strontium is located in bone formed during treatment with a maintained degree of mineralization. Osteoporos Int (2009) 1.07
The role of mineralization and organic matrix in the microhardness of bone tissue from controls and osteoporotic patients. Bone (2008) 1.07
Should we use fluoride to treat osteoporosis? A review. Q J Med (1984) 1.07
Biochemical effects of calcium and vitamin D supplementation in elderly, institutionalized, vitamin D-deficient patients. Rev Rhum Engl Ed (1996) 1.06
Bilateral fractures of femoral neck in patients with moderate renal failure receiving fluoride for spinal osteoporosis. Br Med J (Clin Res Ed) (1983) 1.06
Use of clinical risk factors in elderly women with low bone mineral density to identify women at higher risk of hip fracture: The EPIDOS prospective study. Osteoporos Int (2002) 1.05
Lumbar bone mineral content measured by dual energy X-ray absorptiometry in newborns and infants. Acta Paediatr (1992) 1.05
A clinical approach to diagnosis and management of Paget's disease of bone. J Bone Miner Res (2001) 1.04
Relationship between vitamin D status and skin phototype in general adult population. Photochem Photobiol (2000) 1.02
Marrow changes in paraplegic patients. Calcif Tissue Int (1984) 1.02
Serum estradiol and sex hormone-binding globulin and the risk of hip fracture in elderly women: the EPIDOS study. J Bone Miner Res (2000) 1.01
Fluorotoxic metabolic bone disease: an osteo-renal syndrome caused by excess fluoride ingestion in the tropics. Bone (2006) 1.00
Bone loss in hypothyroidism with hormone replacement. A histomorphometric study. Arch Intern Med (1986) 1.00
Predictive value of desferrioxamine infusion test for bone aluminium deposits in hemodialyzed patients. Nephron (1985) 1.00
Skeletal distribution and biochemical parameters of Paget's disease. Clin Orthop Relat Res (1987) 1.00
Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone (1996) 1.00
Effects of intravenous etidronate and oral corticosteroids in fibrodysplasia ossificans progressiva. Clin Orthop Relat Res (1998) 1.00
The need for clinical guidance in the use of calcium and vitamin D in the management of osteoporosis: a consensus report. Osteoporos Int (2004) 1.00
Impaired osteoblast function in osteoporosis: comparison between calcium balance and dynamic histomorphometry. Br Med J (Clin Res Ed) (1984) 0.98
Ultrasound measurements on os calcis: precision and age-related changes in a normal female population. Osteoporos Int (1993) 0.98
Risk factors for hip fracture in women with high BMD: EPIDOS study. Osteoporos Int (2004) 0.98
Paget's disease of bone: diagnosis and management. BMJ (1996) 0.98
Separate and combined value of bone mass and gait speed measurements in screening for hip fracture risk: results from the EPIDOS study. Epidémiologie de l'Ostéoporose. Osteoporos Int (1999) 0.98
Skeletal blood flow, iliac histomorphometry, and strontium kinetics in osteoporosis: a relationship between blood flow and corrected apposition rate. J Clin Endocrinol Metab (1988) 0.97
Effects of ethane-1 hydroxy-1, 1-diphosphonate (5 mg/kg/day dose) on quantitative bone histology in Paget's disease of bone. Metab Bone Dis Relat Res (1981) 0.96
Role of polyunsaturated fatty acids in the inhibitory effect of human adipocytes on osteoblastic proliferation. Bone (2002) 0.96
Estimation of direct unit costs associated with non-vertebral osteoporotic fractures in five European countries. Rheumatol Int (2006) 0.96
Long term effects of dichloromethylene diphosphonate in Paget's disease of bone. J Clin Endocrinol Metab (1982) 0.96
Fluoride therapy for the vertebral crush fracture syndrome. A status report. Ann Intern Med (1989) 0.96
Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis. Osteoporos Int (2007) 0.95
Inhibition by diphosphonates of bone resorption induced by the Walker tumor of the rat. Cancer Res (1984) 0.95
The mineralization of bone tissue: a forgotten dimension in osteoporosis research. Osteoporos Int (2003) 0.95
Dual energy x-ray absorptiometry measurement of bone mineral content in newborns: validation of the technique. Pediatr Res (1992) 0.95
Sciatica caused by epidural gas. Four case reports. Joint Bone Spine (2001) 0.95
Clinical utility of bone mass measurements in adults: consensus of an international panel. The Society for Clinical Densitometry. Semin Arthritis Rheum (1996) 0.95